Search

Your search keyword '"Beniguel, Lydie"' showing total 19 results
Start Over Author "Beniguel, Lydie"
19 results on '"Beniguel, Lydie"'

1. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Author

Trøseid, Marius, Arribas, José R., Assoumou, Lambert, Holten, Aleksander Rygh, Poissy, Julien, Terzić, Vida, Mazzaferri, Fulvia, Baño, Jesús Rodríguez, Eustace, Joe, Hites, Maya, Joannidis, Michael, Paiva, José-Artur, Reuter, Jean, Püntmann, Isabel, Patrick-Brown, Thale D. J. H., Westerheim, Elin, Nezvalova-Henriksen, Katerina, Beniguel, Lydie, Dahl, Tuva Børresdatter, Bouscambert, Maude, Halanova, Monika, Péterfi, Zoltán, Tsiodras, Sotirios, Rezek, Michael, Briel, Matthias, Ünal, Serhat, Schlegel, Martin, Ader, Florence, Lacombe, Karine, Amdal, Cecilie Delphin, Rodrigues, Serge, Tonby, Kristian, Gaudet, Alexandre, Heggelund, Lars, Mootien, Joy, Johannessen, Asgeir, Møller, Jannicke Horjen, Pollan, Beatriz Diaz, Tveita, Anders Aune, Kildal, Anders Benjamin, Richard, Jean-Christophe, Dalgard, Olav, Simensen, Victoria Charlotte, Baldé, Aliou, de Gastines, Lucie, del Álamo, Marta, Aydin, Burç, Lund-Johansen, Fridtjof, Trabaud, Mary-Anne, Diallo, Alpha, Halvorsen, Bente, Røttingen, John-Arne, Tacconelli, Evelina, Yazdanpanah, Yazdan, Olsen, Inge C., and Costagliola, Dominique

Published
2023
Full Text
View/download PDF

2. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study

Author

Molina, Jean-Michel, Ghosn, Jade, Assoumou, Lambert, Delaugerre, Constance, Algarte-Genin, Michèle, Pialoux, Gilles, Katlama, Christine, Slama, Laurence, Liegeon, Geoffroy, Beniguel, Lydie, Ohayon, Michel, Mouhim, Hanane, Goldwirt, Lauriane, Spire, Bruno, Loze, Bénédicte, Surgers, Laure, Pavie, Juliette, Lourenco, Jérémy, Ben-Mechlia, Mohamed, Le Mestre, Soizic, Rojas-Castro, Daniela, and Costagliola, Dominique

Published
2022
Full Text
View/download PDF

4. High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022.

Author

Palich, Romain, Arias-Rodríguez, Andrés, Duracinsky, Martin, Le Talec, Jean-Yves, Torrente, Olivia Rousset, Lascoux-Combe, Caroline, Lacombe, Karine, Ghosn, Jade, Viard, Jean-Paul, Pialoux, Gilles, Ohayon, Michel, Duvivier, Claudine, Velter, Annie, Mechlia, Mohamed Ben, Beniguel, Lydie, Grabar, Sophie, Melchior, Maria, Assoumou, Lambert, and Supervie, Virginie

Published
2024
Full Text
View/download PDF

5. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Author

European Commission, Trøseid, Marius, Arribas, José Ramón, Assoumou, Lambert, Holten, Aleksander Rygh, Poissy, Julien, Terzić, Vida, Mazzaferri, Fulvia, Rodríguez-Baño, Jesús, Eustace, Joe, Hites, Maya, Joannidis, Michael, Paiva, Jose‑Artur, Reuter, Jean, Püntmann, Isabel, Patrick-Brown, Thale D. J. H., Westerheim, Elin, Nezvalova-Henriksen, Katerina, Beniguel, Lydie, Dahl, Tuva Børresdatter, Bouscambert, Maude, Halanova, Monika, Péterfi, Zoltán, Tsiodras, Sotirios, Rezek, Michael, Briel, Matthias, Ünal, Serhat, Schlegel, Martin, Ader, Florence, Lacombe, Karine, Amdal, Cecilie Delphin, Rodrigues, Serge, Tonby, Kristian, Gaudet, Alexandre, Heggelund, Lars, Mootien, Joy, Johannessen, Asgeir, Møller, Jannicke Horjen, Díaz-Pollán, Beatriz, Tveita, Anders Aune, Kildal, Anders Benjamin, Richard, Jean-Christophe, Dalgard, Olav, Simensen, Victoria Charlotte, Baldé, Aliou, Gastines, Lucie de, Álamo, Marta del, Aydin, Burç, Lund-Johansen, Fridtjof, Trabaud, Mary-Anne, Diallo, Alpha, Halvorsen, Bente, Røttingen, John-Arne, Tacconelli, Evelina, Yazdanpanah, Yazdan, Olsen, Inge C., Costagliola, Dominique, EU SolidAct study group, European Commission, Trøseid, Marius, Arribas, José Ramón, Assoumou, Lambert, Holten, Aleksander Rygh, Poissy, Julien, Terzić, Vida, Mazzaferri, Fulvia, Rodríguez-Baño, Jesús, Eustace, Joe, Hites, Maya, Joannidis, Michael, Paiva, Jose‑Artur, Reuter, Jean, Püntmann, Isabel, Patrick-Brown, Thale D. J. H., Westerheim, Elin, Nezvalova-Henriksen, Katerina, Beniguel, Lydie, Dahl, Tuva Børresdatter, Bouscambert, Maude, Halanova, Monika, Péterfi, Zoltán, Tsiodras, Sotirios, Rezek, Michael, Briel, Matthias, Ünal, Serhat, Schlegel, Martin, Ader, Florence, Lacombe, Karine, Amdal, Cecilie Delphin, Rodrigues, Serge, Tonby, Kristian, Gaudet, Alexandre, Heggelund, Lars, Mootien, Joy, Johannessen, Asgeir, Møller, Jannicke Horjen, Díaz-Pollán, Beatriz, Tveita, Anders Aune, Kildal, Anders Benjamin, Richard, Jean-Christophe, Dalgard, Olav, Simensen, Victoria Charlotte, Baldé, Aliou, Gastines, Lucie de, Álamo, Marta del, Aydin, Burç, Lund-Johansen, Fridtjof, Trabaud, Mary-Anne, Diallo, Alpha, Halvorsen, Bente, Røttingen, John-Arne, Tacconelli, Evelina, Yazdanpanah, Yazdan, Olsen, Inge C., Costagliola, Dominique, and EU SolidAct study group

Abstract

[Background] Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants., [Methods] Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients with severe/critical COVID-19 were randomised to Baricitinib 4 mg once daily or placebo, added to standard of care. The primary endpoint was all-cause mortality within 60 days. Participants were remotely followed to day 90 for safety and patient related outcome measures., [Results] Two hundred ninety-nine patients were screened, 284 randomised, and 275 received study drug or placebo and were included in the modified intent-to-treat analyses (139 receiving baricitinib and 136 placebo). Median age was 60 (IQR 49–69) years, 77% were male and 35% had received at least one dose of SARS-CoV2 vaccine. There were 21 deaths at day 60 in each group, 15.1% in the baricitinib group and 15.4% in the placebo group (adjusted absolute difference and 95% CI − 0.1% [− 8·3 to 8·0]). In sensitivity analysis censoring observations after drug discontinuation or rescue therapy (tocilizumab/increased steroid dose), proportions of death were 5.8% versus 8.8% (− 3.2% [− 9.0 to 2.7]), respectively. There were 148 serious adverse events in 46 participants (33.1%) receiving baricitinib and 155 in 51 participants (37.5%) receiving placebo. In subgroup analyses, there was a potential interaction between vaccination status and treatment allocation on 60-day mortality. In a subsequent post hoc analysis there was a significant interaction between vaccination status and treatment allocation on the occurrence of serious adverse events, with more respiratory complications and severe infections in vaccinated participants treated with baricitinib. Vaccinated participants were on average 11 years older, with more comorbidities., [Conclusion] This clinical trial was prematurely stopped for external evidence and therefore underpowered to conclude on a potential survival benefit of baricitinib in severe/critical COVID-19. We observed a possible safety signal in vaccinated participants, who were older with more comorbidities. Although based on a post-hoc analysis, these findings warrant further investigation in other trials and real-world studies. Trial registration Bari-SolidAct is registered at NCT04891133 (registered May 18, 2021) and EUClinicalTrials.eu (2022-500385-99-00).

Published
2023

6. Additional file 1 of Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Author

Trøseid, Marius, Arribas, José R., Assoumou, Lambert, Holten, Aleksander Rygh, Poissy, Julien, Terzić, Vida, Mazzaferri, Fulvia, Baño, Jesús Rodríguez, Eustace, Joe, Hites, Maya, Joannidis, Michael, Paiva, José-Artur, Reuter, Jean, Püntmann, Isabel, Patrick-Brown, Thale D. J. H., Westerheim, Elin, Nezvalova-Henriksen, Katerina, Beniguel, Lydie, Dahl, Tuva Børresdatter, Bouscambert, Maude, Halanova, Monika, Péterfi, Zoltán, Tsiodras, Sotirios, Rezek, Michael, Briel, Matthias, Ünal, Serhat, Schlegel, Martin, Ader, Florence, Lacombe, Karine, Amdal, Cecilie Delphin, Rodrigues, Serge, Tonby, Kristian, Gaudet, Alexandre, Heggelund, Lars, Mootien, Joy, Johannessen, Asgeir, Møller, Jannicke Horjen, Pollan, Beatriz Diaz, Tveita, Anders Aune, Kildal, Anders Benjamin, Richard, Jean-Christophe, Dalgard, Olav, Simensen, Victoria Charlotte, Baldé, Aliou, de Gastines, Lucie, del Álamo, Marta, Aydin, Burç, Lund-Johansen, Fridtjof, Trabaud, Mary-Anne, Diallo, Alpha, Halvorsen, Bente, Røttingen, John-Arne, Tacconelli, Evelina, Yazdanpanah, Yazdan, Olsen, Inge C., and Costagliola, Dominique

Abstract

Additional file 1. Online Appendix.

Published
2023
Full Text
View/download PDF

7. Implementation of a centralized pharmacovigilance system in academic pan‐European clinical trials : experience from EU‐Response and conect4children consortia

Author

Terzić, Vida, Levoyer, Léa, Figarella, Mélanie, Bigagli, Elisabetta, Mercier, Noémie, De Gastines, Lucie, Gibowski, Séverine, Trøseid, Marius, Demotes, Jacques, Olsen, Inge Christoffer, Hites, Maya, Ader, Florence, Lopez, José Ramón Arribas, Mentré, France, Espérou, Hélène, Costagliola, Dominique, Røttingen, John‐Arne, Poissy, Julien, Rozé, Jean‐Christophe, Warris, Adilia, O'Leary, Jackie, Fernandes, Ricardo M., Assoumou, Lambert, Hankard, Regis, Turner, Mark, Yazdanpanah, Yazdan, Diallo, Alpha, Holten, Aleksander Rygh, Barratt‐Due, Andreas, Westerheim, Elin, Colban, Martha, Tonby, Kristian, Peiffer‐Smadja, Nathan, Eustace, Joe, Keane, Ruben E., Arribàs, José R., Garcia, Irene, Mazzaferri, Fulvia, Grimaldi, David, Reuter, Jean, Staub, Therese, Berchem, Guy, Delmas, Christelle, Saillard, Juliette, Fougerou‐Leurent, Claire, Ferrane, Assia, Beniguel, Lydie, Baldé, Aliou, Belhadi, Drifa, Dechanet, Aline, Andrejak, Claire, Del Alamo, Marta, Luz, Filipa, Greil, Richard, Keuschnig, Alexandra, Hajdu, Edit, Halanova, Monika, Troníčková, Radka, Trojanek, Milan, Nerušilová, Katerina, Piekarska, Anna, Wiesner, Agnieszka, Bano, Jesus, Tsiodras, Sotirios, Ladenstein, Ruth, Vande Walle, Johan, Degraeuwe, Eva, Kvamme, Anne Mathilde H., Rajasaar, Héli, Kallio, Jaana, Papazisis, Georgios, László, Bálint, O'cleary, Jackie, Ryszard, Sot, Sousa, Catarina, Rodríguez‐Tenreiro, Carmen, Kindblom, Jenny, Ruegger, Christoph, Möller, Alexander, Hawcutt, Daniel, van der Geest, Tessa, Bruggemann, Roger, Neubert, Antje, Drouard, Anne, Dumousseaux, Marina, Moal, Anaelle, Michon, Amelie, Bouazza, Naim, Ursino, Moreno, Hervé, Magali, Boussaha, Inesse, Lozano, Helene, Gueyffier, Francois, Dilo, Ana, Negrini, Anna, Di Maggio, Lucia, Rocchi, Francesca, Polikar, Betty, Cook, Heather, EU‐Response safety group, [missing], and c4c safety group, [missing]

Subjects
Pharmacology, paediatrics, clinical trials, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], drug safety, pharmacovigilance, public health, Medicine and Health Sciences, Pharmacology (medical)
Abstract

Contains fulltext : 292812.pdf (Publisher’s version ) (Open Access) Setting-up a high quality, compliant and efficient pharmacovigilance (PV) system in multi-country clinical trials can be more challenging for academic sponsors than for companies. To ensure the safety of all participants in academic studies and that the PV system fulfils all regulations, we set up a centralized PV system that allows sponsors to delegate work on PV. This initiative was put in practice by our Inserm-ANRS MIE PV department in two distinct multinational European consortia with 19 participating countries: conect4children (c4c) for paediatrics research and EU-Response for Covid-19 platform trials. The centralized PV system consists of some key procedures to harmonize the complex safety processes, creation of a local safety officer (LSO) network and centralization of all safety activities. The key procedures described the safety management plan for each trial and how tasks were shared and delegated between all stakeholders. Processing of serious adverse events (SAEs) in a unique database guaranteed the full control of the safety data and continuous evaluation of the risk-benefit ratio. The LSO network participated in efficient regulatory compliance across multiple countries. In total, there were 1312 SAEs in EU-Response and 83 SAEs in c4c in the four trials. We present here the lessons learnt from our experience in four clinical trials. We managed heterogeneous European local requirements and implemented efficient communication with all trial teams. Our approach builds capacity for PV that can be used by multiple academic sponsors.

Published
2023

9. Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study

Author

Liegeon, Geoffroy, primary, Assoumou, Lambert, additional, Ghosn, Jade, additional, El Mouhebb, Mayssam, additional, Palich, Romain, additional, Palacios, Christia, additional, Slama, Laurence, additional, Surgers, Laure, additional, Genin, Michèle, additional, Beniguel, Lydie, additional, Goldwirt, Lauriane, additional, Duvivier, Claudine, additional, Rojas Castro, Daniela, additional, Costagliola, Dominique, additional, and Molina, Jean-Michel, additional

Published
2022
Full Text
View/download PDF

10. Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

Author

Trøseid, Marius, primary, Arribas, JR, additional, Assoumou, Lambert, additional, Holten, Aleksander Rygh, additional, Poissy, Julien, additional, Terzić, Vida, additional, Mazzaferri, Fulvia, additional, Rodríguez-Baño, Jesús , additional, Eustace, Joe, additional, Hites, Maya, additional, Joannidis, Michael, additional, Paiva, Jose-Artur, additional, Reuter, Jean, additional, Püntmann, Isabel, additional, Patrick-Brown, Thale, additional, Westerheim, Elin, additional, Nezvalova-Henriksen, Katerina, additional, Beniguel, Lydie, additional, Dahl, Tuva Børresdatter, additional, Bouscambert-Duchamp, Maude, additional, Halanova, Monika, additional, Peterfi, Zoltan, additional, Tsiodras, Sotirios, additional, Rezek, Michael, additional, Briel, Matthias, additional, Unal, Serhat, additional, Schlegel, Martin, additional, Ader, Florence, additional, Lacombe, Karine, additional, Amdal, Cecilie Delphin, additional, Serge Rodrigues, Serge Rodrigues, additional, Tonby, Kristian, additional, Gaudet, Alexandre, additional, Heggelund, Lars, additional, Mootien, Joy, additional, Johannessen, Asgeir, additional, Møller, Jannicke Horjen, additional, Diaz Pollan, Beatriz, additional, Tveita, Anders, additional, Kildal, Anders Benjamin, additional, Richard, Jean-Christophe, additional, Dalgard, Olav, additional, Simensen, Victoria Charlotte, additional, Baldé, Aliou, additional, de Gastines, Lucie, additional, del Álamo, Marta, additional, Aydin, Burç, additional, Lund-Johansen, Fridtjof, additional, Trabaud, Mary-Anne, additional, Diallo, Alpha, additional, Halvorsen, Bente, additional, Røttingen, John-Arne, additional, Tacconelli, Evelina, additional, Yadanapanah, Yazdan, additional, Olsen, Inge Christoffer, additional, and Costagliola, Dominique, additional

Published
2022
Full Text
View/download PDF

11. Characterization of Viral Rebounds on Dual Etravirine/Raltegravir Maintenance Therapy

Author

Soulie, Cathia, Assoumou, Lambert, Abdi, Basma, Sayon, Sophie, Nguyen, Thuy, Valantin, Marc-Antoine, Beniguel, Lydie, Ferre, Virginie, Alloui, Chakib, Montes, Brigitte, Avettand-Fenoel, Véronique, Delaugerre, Constance, Descamps, Diane, Martinez, Esteban, Reynes, Jacques, Peytavin, Gilles, Costagliola, Dominique, Katlama, Christine, Calvez, Vincent, Marcelin, Anne-Geneviève, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Virologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière], Service de virologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de bactériologie-Virologie-Hygiène [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Nord, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Gestionnaire, Hal Sorbonne Université, Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de virologie [CHU Pitié-Salpêtrière], Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

International audience; Background: The ANRS-163 ETRAL trial, a switch study to an etravirine 200 mg/raltegravir 400 mg twice-daily regimen in 165 patients with HIV-1 infection, showed durable efficacy until Week 96. The aim of this work was to investigate in detail the virological rebounds (VRs), defined as at least one plasma HIV viral load (VL) >50 copies/mL.Methods: Quantification of HIV-DNA level was assessed at baseline, Week 48 and Week 96 (n = 157). VLs were measured in seminal plasma at Week 48 (n = 26). Genotypic resistance testing by ultra-deep sequencing (UDS) for reverse transcriptase (RT) and integrase regions was performed at baseline and at the time of VR.Results: In this study, 19 patients experienced VR, with 2 patients having virological failure (VF; two consecutive VLs >50 copies/mL). For the first patient with VF, UDS detected minority resistant variants only in RT (K103N, 9.6%; Y181C, 4.9%) at baseline. Some RT variants became dominant at VF (K101E, 86.3%; Y181C, 100.0%; G190A, 100.0%) and others emerged in integrase (Y143C, 2.4%; Q148R, 6.2%; N155H, 18.8%). For the second patient with VF, neither RT nor integrase mutations were detected at baseline and VF. Median HIV-DNA level was similar at baseline, Week 48 and Week 96 (2.17, 2.06 and 2.11 log10 copies/106 cells, respectively). Only one patient had a detectable seminal HIV VL (505 copies/mL).Conclusions: The dual etravirine/raltegravir regimen as maintenance therapy was effective and the emergence of mutations in cases of VF was similar to that seen in other dual-regimen studies. No HIV-DNA level modification was evidenced by Week 96.

Published
2020
Full Text
View/download PDF

12. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts

Author

Delaugerre, Constance, Assoumou, Lambert, Maylin, Sarah, Minier, Marine, Gabassi, Audrey, Genin, Michèle, Beniguel, Lydie, Ghosn, Jade, Lamballerie, Xavier de, Mouhebb, Mayssam El, Costagliola, Dominique, Carrat, Fabrice, Molina, Jean Michel, and Groups, for the PREVENIR and SAPRIS-Sero Study

Subjects
SARS-CoV-2, VIRAL hepatitis
Abstract

The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar in PrEP users and in a matched population-based cohort, suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. Clinical and Virological Study of Dengue Cases and the Members of Their Households: The Multinational DENFRAME Project

Author

Dussart, Philippe, primary, Baril, Laurence, additional, Petit, Laure, additional, Beniguel, Lydie, additional, Quang, Luong Chan, additional, Ly, Sowath, additional, Azevedo, Raimunda do Socorro Silva, additional, Meynard, Jean-Baptiste, additional, Vong, Sirenda, additional, Chartier, Loïc, additional, Diop, Aba, additional, Sivuth, Ong, additional, Duong, Veasna, additional, Thang, Cao Minh, additional, Jacobs, Michael, additional, Sakuntabhai, Anavaj, additional, Nunes, Marcio Roberto Teixeira, additional, Huong, Vu Ti Que, additional, Buchy, Philippe, additional, and Vasconcelos, Pedro Fernando da Costa, additional

Published
2012
Full Text
View/download PDF

19. High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022.

Author

Palich R, Arias-Rodríguez A, Duracinsky M, Le Talec JY, Rousset Torrente O, Lascoux-Combe C, Lacombe K, Ghosn J, Viard JP, Pialoux G, Ohayon M, Duvivier C, Velter A, Ben Mechlia M, Beniguel L, Grabar S, Melchior M, Assoumou L, and Supervie V

Subjects
Male, Humans, Adolescent, Homosexuality, Male, Paris epidemiology, Cross-Sectional Studies, Sexual Behavior, France epidemiology, HIV Infections diagnosis, HIV Infections epidemiology, HIV Infections prevention & control, Transients and Migrants, Sexual and Gender Minorities
Abstract

BackgroundSome migrant men who have sex with men (MSM) acquire HIV in France.AimsWe investigated, in migrant MSM receiving HIV care in France, the (i) rate of post-migration-HIV acquisition in France, (ii) delay between arrival and HIV acquisition and (iii) factors affecting HIV acquisition within 1 year after migration.MethodsThis cross-sectional study focused on ≥ 18-year-old MSM born outside France, receiving HIV care in the Paris region. Information on migration history, socioeconomic condition, sexual activity, and health was collected in May 2021-June 2022 through self-administered questionnaires and medical records. Post-migration-HIV-acquisition rate and delay between arrival in France and HIV acquisition were estimated from biographical data and CD4+ T-cell counts. Predictors of HIV acquisition within 1 year after migration were determined using logistic regression.ResultsOverall post-migration HIV-acquisition rate was 61.7% (715/1,159; 95%CI: 61.2-62.2), ranging from 40.5% (95%CI: 39.6-41.6) to 85.4% (95%CI: 83.9-86.0) in participants from Latin America and North Africa. Among post-migration-HIV acquisitions, those within 1 year after migration represented 13.1% overall (95%CI: 11.6-14.6), being highest in participants from sub-Saharan Africa (25%; 95%CI: 21.5-28.3). Participants ≥ 15-years old at migration, with post-migration-acquired HIV, had a 7.5-year median interval from arrival in France to HIV acquisition (interquartile range (IQR): 3.50-14.75). Older age at arrival, region of origin (sub-Saharan Africa and Asia), degree of social disadvantage and numbers of sexual partners were independently associated with acquiring HIV within 1 year in France.ConclusionOur findings may guide HIV prevention policies for most vulnerable migrants to Europe.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results